When is URGN's latest earnings report released?
The most recent financial report for Urogen pharma ltd. (URGN) covers the period of 2025Q4 and was published on 2025/12/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating URGN's short-term business performance and financial health. For the latest updates on URGN's earnings releases, visit this page regularly.
What is the operating profit of URGN?
According to the latest financial report, Urogen pharma ltd. (URGN) reported an Operating Profit of -19.12M with an Operating Margin of -50.52% this period, representing a growth of 30.89% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.
How is URGN's revenue growth?
In the latest financial report, Urogen pharma ltd. (URGN) announced revenue of 37.84M, with a Year-Over-Year growth rate of 54.03%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.
How much cash does URGN have?
At the end of the period, Urogen pharma ltd. (URGN) held Total Cash and Cash Equivalents of 112.1M, accounting for 0.56 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.
Does URGN go with three margins increasing?
In the latest report, Urogen pharma ltd. (URGN) did not achieve the “three margins increasing” benchmark, with a gross margin of 91.3%%, operating margin of -50.52%%, and net margin of -69.7%%. This demonstrates limited improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess URGN's profit trajectory and future growth potential.
Is URGN's EPS continuing to grow?
According to the past four quarterly reports, Urogen pharma ltd. (URGN)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at -0.53. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.
What is the FCF of URGN?
Urogen pharma ltd. (URGN)'s Free Cash Flow (FCF) for the period is -38.34M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 179.18% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.
What are the PEG ratio and PE ratio of URGN?
The latest valuation data shows Urogen pharma ltd. (URGN) has a Price-To-Earnings (PE) ratio of -6.03 and a Price/Earnings-To-Growth (PEG) ratio of 0.5. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.
